Investing.com - Health Catalyst (NASDAQ: HCAT) reported third quarter EPS of $0.07, $0.03 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $76.4M versus the consensus estimate of $76.27M.
Guidance
Health Catalyst sees Q4 2024 revenue of $78.00M-$84.00M versus the analyst consensus of $80.66M.
Health Catalyst's stock price closed at $8.25. It is up 24.06% in the last 3 months and up 14.58% in the last 12 months.
Health Catalyst saw 3 positive EPS revisions and 7 negative EPS revisions in the last 90 days. See Health Catalyst's stock price’s past reactions to earnings here.
According to InvestingPro, Health Catalyst's Financial Health score is "good performance".
Check out Health Catalyst's recent earnings performance, and Health Catalyst's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar